Initially, injection of CRC tumor cells enriched prior to implantation for cells expressing the putative CRC stem cell marker CD133+ was compared with injection of bulk, unsorted tumor cells for establishing xenografts because the former has been associated with a higher probability of engraftment [1], [2]. The gene discussed is PROM1; the disease is neoplasm.